IGF2BP3 Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia

Artturi Mäkinen 1,2,*, Atte Nikkilä 3, Teppo Haapaniemi 2,3, Laura Oksa 3, Juha Mehtonen 4, Matti Vänskä 5, Merja Heinäniemi 4, Timo Paavonen 2,6 and Olli Lohi 1,7

1 Tampere Center for Child, Adolescent and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland; atte.nikkila@tuni.fi (A.N.); laura.oksa@tuni.fi (L.O.); olli.lohi@tuni.fi (O.L.)
2 Fimlab Laboratories, Department of Pathology, Tampere University Hospital, 33520 Tampere, Finland; teppo.haapaniemi@fimlab.fi (T.H.); timo.paavonen@tuni.fi (T.P.)
3 Department of Biological and Environmental Sciences, University of Jyväskylä, 40014 Jyväskylä, Finland
4 Institute of Biomedicine, School of Medicine, University of Eastern Finland, 70211 Kuopio, Finland; juha.mehtonen@uef.fi (J.M.); merja.heinaniemi@uef.fi (M.H.)
5 Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland; matti.vanska@psph.fi
6 Department of Pathology, Faculty of Medicine and Health Technology, Tampere University, 33520 Tampere, Finland
7 Tays Cancer Centre, Tampere University Hospital, 33520 Tampere, Finland

* Correspondence: artturi.makinen@tuni.fi

Figure S1. Immunohistochemical co-staining of CD19 and Ki-67 in B-ALL. (A) CD19 (red) and Ki-67 (brown) in the appendix show a high expression of Ki-67 in the germinal center (upper right) and crypt epithelium (lower left; 200X magnification). (B) Co-staining of CD19 and Ki-67 in the B-ALL case with a high proportion of blasts showing positivity to nuclear Ki-67 staining. (C) B-ALL case showing partial expression of the nuclear Ki-67 protein (200X magnification).


Academic Editor: Ajay Pratap Singh

Received: 13 February 2021
Accepted: 22 March 2021
Published: 25 March 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Figure S2. Heatmap illustration of the expression of proliferation-associated genes (MKI67, PCNA, CCNB1, MCM2, and TOP2A) in cases with either a high or low expression of IGF2BP3 [29]. (A) Heatmap illustrations using (A) all hematological cancers or (B) B-ALL from the Hemap data set [24,25], and (C) B-ALL cases from the PanALL data set [26].
Figure S3. Boxplots showing expression of CDK6 and MYC in cases with either a low or high expression of IGF2BP3 in B-ALL for both of the data sets: (A,B) PanALL data set and (C,D) Hemap data set [24–26]. Dots represent outliers. The $p$-values of the Mann–Whitney U tests between groups are shown.